Augustin M, Mcbride D, Gilloteau I, O'Neill C, Neidhardt K, Graham CN. Cost-effectiveness of secukinumab as first biologic treatment, compared with other biologics, for moderate to severe psoriasis in Germany. J Eur Acad Dermatol Venereol. 2018 Dec;32(12):2191-9. doi: 10.1111/jdv.15047
Warren RB, Halliday A, Graham CN, Gilloteau I, Miles L, Mcbride D. Secukinumab significantly reduces psoriasis-related work impairment and indirect costs compared with ustekinumab and etanercept in the United Kingdom. J Eur Acad Dermatol Venereol. 2018 Dec;32(12):2178-84. doi: 10.1111/jdv.15094
Augustin M, Abeysinghe S, Mallya U, Qureshi A, Roskell N, Mcbride D, Papavassillis C, Gelfand J. Secukinumab treatment of plaque psoriasis shows early improvement in DLQI response - results of a phase II regimen-finding trial. J Eur Acad Dermatol Venereol. 2016 Apr;30(4):645-9. doi: 10.1111/jdv.13478
Bauman KE, Foshee VA, Ennett ST, Hicks K, Pemberton M. Family matters: a family-directed program designed to prevent adolescent tobacco and alcohol use. Health Promot Pract. 2001 Jan 1;2(1):81-96.
Smart JD, Nicholls TJ, Green KL, Rogers DJ, Cook JD, Wolowacz SE. Lectins in drug delivery: an in vivo toxicity study of the lectins from Solanum tuberosum and Helix pomatia. J Pharm Pharmacol. 1998 Sep.
Nicholls TJ, Cook DJ, Rogers DJ, Wolowacz SE, Smart JD. An investigation of lectin binding sites within the precorneal region. J Pharm Pharmacol. 1994;46:1050.